Fig. 6

The effect of Aβ administration on p35 expression and immunoreactivity in hippocampus. Aβ (0.5 nmol) was injected intracerebroventricularly. a Gene expression for Cdk5r1 was analysed 3 h and 1, 3, 7 and 14 days after injection by quantitative RT-PCR. b Immunoreactivity of p35 and its degradation product p25 was analysed 3 h and 1, 3, 7 and 14 days after injection by SDS-PAGE and Western blotting. Representative pictures were shown. Results of densitometric analysis were normalised to immunoreactivity of GAPDH, as a loading control. The results are presented as the mean ± SEM from four independent experiments (n = 4). ***p < 0.001 compared with the respective control. c Scrambled Aβ does not change the immunoreactivity of p35 and its degradation product p25 3 h after injection. Representative pictures were shown. Results of densitometric analysis were normalised to immunoreactivity of GAPDH, as a loading control. Results are presented as the mean ± SEM from four independent experiments (n = 4). **p < 0.01 compared with the respective control (solvent injected animals), ^##p < 0.01 compared with the Aβ-treated animals using a one-way ANOVA followed by the Bonferroni test